Literature DB >> 21269935

Relationship between model for end-stage liver disease score and left ventricular function in patients with end-stage liver disease.

Fu-Rong Sun1, Ying Wang, Bing-Yuan Wang, Jing Tong, Dai Zhang, Bing Chang.   

Abstract

BACKGROUND: Decreased cardiac contractility has been observed in cirrhosis, suggesting a latent cardiomyopathy in these patients. This study was designed to evaluate left ventricular structure and function in patients with end-stage liver disease by the model for end-stage liver disease (MELD) scoring system.
METHODS: We recruited 82 patients (72 male, 10 female; mean age 50.3+/-8.9 years) with end-stage liver disease who underwent orthotopic liver transplantation between January 2002 and May 2008. Seventy-eight patients had cirrhosis and 4 had primary liver cancer. Patients were categorized into three groups on the basis of MELD score: ≤ 9 (27 patients, 33%); 10-19 (40, 49%); and ≥ 20 (15, 18%). The relationship between MELD score and cardiac structure and function was determined. Preoperative assessments of blood biochemistry, blood coagulation, serum virology, echocardiography and electrocardiography were performed.
RESULTS: MELD score was positively correlated with enlarged left atrial diameter, increased interventricular septum thickness (IVST), increased aortic flow, corrected QT interval (QTc) extension and cardiac output (P=0.033, 0.002, 0.000, 0.000 and 0.009, respectively). International normalized ratio also had a correlation with the above parameters and enlarged left ventricular end-diastolic diameter (P=0.043, 0.010, 0.000, 0.001, 0.016 and 0.008, respectively). Serum creatinine was positively correlated with IVST (r=0.257, P=0.020), but negatively correlated with early maximal ventricular filling velocity/late diastolic or atrial velocity ratio (r=-0.300, P=0.006). A difference of QTc >440 ms among the three groups was statistically significant (X2=9.791, P=0.007).
CONCLUSIONS: Abnormalities in cardiac structure and function are common in patients with end-stage liver disease. MELD score is a practically useful approach for the assessment of cardiac function in such patients.

Entities:  

Mesh:

Year:  2011        PMID: 21269935     DOI: 10.1016/s1499-3872(11)60007-6

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  5 in total

1.  Cirrhosis-related changes in left ventricular function and correlation with the model for end-stage liver disease score.

Authors:  Xiaopeng Li; Shanshan Yu; Lu Li; Donggang Han; Shejiao Dai; Ya Gao
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  The end-organ impairment in liver cirrhosis: appointments for critical care.

Authors:  Antonio Figueiredo; Francisco Romero-Bermejo; Rui Perdigoto; Paulo Marcelino
Journal:  Crit Care Res Pract       Date:  2012-05-16

3.  Impact of hyponatremia on frequency of complications in patients with decompensated liver cirrhosis.

Authors:  Ashraf Abd El-Khalik Barakat; Amna Ahmed Metwaly; Fatma Mohammad Nasr; Maged El-Ghannam; Mohamed Darwish El-Talkawy; Hoda Abu Taleb
Journal:  Electron Physician       Date:  2015-10-19

4.  Model for End-Stage Liver Disease Score Predicts the Mortality of Patients with Coronary Heart Disease Who Underwent Percutaneous Coronary Intervention.

Authors:  You Chen; Min Han; Ying-Ying Zheng; Feng Zhu; Aikebai Aisan; Tunike Maheshati; Yi-Tong Ma; Xiang Xie
Journal:  Cardiol Res Pract       Date:  2021-04-17       Impact factor: 1.866

5.  Prevalence of pre-transplant electrocardiographic abnormalities and post-transplant cardiac events in patients with liver cirrhosis.

Authors:  Axel Josefsson; Michael Fu; Einar Björnsson; Evangelos Kalaitzakis
Journal:  BMC Gastroenterol       Date:  2014-04-05       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.